510(k) K223653
K223653 is an FDA 510(k) premarket notification submitted by Becton, Dickinson and Company for the device "BD Vaginal Panel". The FDA issued a decision of Substantially Equivalent on March 6, 2023. The device falls under product code PQA (Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System), a Class II device regulated under 21 CFR 866.3975. Becton, Dickinson and Company has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- March 6, 2023
- Date Received
- December 6, 2022
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System
- Device Class
- Class II
- Regulation Number
- 866.3975
- Review Panel
- MI
- Submission Type
A vaginitis and bacterial vaginosis nucleic acid detection system is a qualitative in vitro diagnostic device for the direct detection of nucleic acid sequences from microorganisms associated with vaginitis or bacterial vaginosis. The device is indicated for individuals with signs and symptoms of vaginitis or bacterial vaginosis and aids in the diagnosis of these vaginal infections.